Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.
Verbal communication in consultations by dermatologists and physicians has an extensive impact on patient engagement in the management of hidradenitis suppurativa (HS), said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by the disease.
Transcript
Can you speak on misconceptions and other care management challenges regarding HS?
I think the only thing is just to reiterate that it's not your fault. I think in so many cases, we go to the doctor as a patient and you're told: Oh, you need to lose weight; oh, you need to make sure that you're washing appropriately. These are all things that we already are fully aware of, and in a lot of cases it's said with such a negative connotation.
I, for instance, when I was 16 and diagnosed, was told that I had a Black woman's disease. So, you take a 16-year-old Caucasian female who already is super uncomfortable in her own skin, and then tell me that I don't even fit in my own disease demographic. That one statement has stuck with me my entire life. I don't think that the physician had any idea the impact that one statement had. It led me to not seek treatment for my HS, because I was concerned that when I would go to the dermatologist, that people would think that I was out of place: “What's wrong with her? She's a Caucasian female at 16—why does she have a Black woman's disease?” What does that even mean? How is that helpful?
Physicians need to be really conscientious of what they say to their patients. They have no idea the impact that one statement can make on someone, their treatment journey, their ability or desire to seek treatment, because we are already feeling out of place. And I think that is a crucial thing that we need to get through to dermatologists and anybody dealing with patients with HS, about being very conscientious about what they say to them and the impact that has on them.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen